NASDAQ:JAZZ

Jazz Pharmaceuticals - JAZZ Stock Forecast, Price & News

$156.54

-0.37 (-0.24%)

(As of 12/1/2022 12:00 AM ET)

Add

Compare

Today's Range: $155.28
▼
$157.49
50-Day Range: $126.59
▼
$156.91
52-Week Range: $119.64
▼
$169.98

Volume: 770,465 shs
Average Volume: 554,149 shs
Market Capitalization: $9.86 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $202.50

Jazz Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.80 Rating Score
Upside/Downside: 29.4% Upside
$202.50 Price Target
Short Interest: Healthy
3.73% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.96
Upright™ Environmental Score
News Sentiment: 0.88
Based on 5 Articles This Week
Insider Trading: Selling Shares
$8.52 M Sold Last Quarter
Proj. Earnings Growth: 9.82%
From $14.77 to $16.22 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.85 out of 5 stars

Medical Sector

53rd out of 1,047 stocks

Pharmaceutical Preparations Industry

22nd out of 512 stocks

3.4

Analyst's Opinion

Consensus Rating
Jazz Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 8 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $202.50, Jazz Pharmaceuticals has a forecasted upside of 29.4% from its current price of $156.54.
Amount of Analyst Coverage
Jazz Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
3.73% of the outstanding shares of Jazz Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Jazz Pharmaceuticals has a short interest ratio ("days to cover") of 4.5.
Change versus previous month
Short interest in Jazz Pharmaceuticals has recently decreased by 1.67%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Jazz Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Jazz Pharmaceuticals does not have a long track record of dividend growth.

4.0

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Jazz Pharmaceuticals has received a 54.43% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Leukemia medication", "Lung cancer medication", and "Anticoagulant medication (B01)" products. See details.
Environmental Sustainability
The Environmental Impact score for Jazz Pharmaceuticals is -1.96.

3.8

News and Social Media Coverage

News Sentiment
Jazz Pharmaceuticals has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Jazz Pharmaceuticals this week, compared to 4 articles on an average week.
Search Interest
19 people have searched for JAZZ on MarketBeat in the last 30 days. This is an increase of 850% compared to the previous 30 days.
MarketBeat Follows
11 people have added Jazz Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 57% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Jazz Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,523,904.00 in company stock.
Percentage Held by Insiders
Only 4.40% of the stock of Jazz Pharmaceuticals is held by insiders.
Percentage Held by Institutions
92.79% of the stock of Jazz Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

2.5

Earnings and Valuation

Earnings Growth
Earnings for Jazz Pharmaceuticals are expected to grow by 9.82% in the coming year, from $14.77 to $16.22 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Jazz Pharmaceuticals is -521.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Jazz Pharmaceuticals is -521.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Growth Ratio
Jazz Pharmaceuticals has a PEG Ratio of 0.93. PEG Ratios below 1 indicate that a company could be undervalued.
Price to Book Value per Share Ratio
Jazz Pharmaceuticals has a P/B Ratio of 3.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: Xyrem, Xywav, Sunosi, Erwinaze, Vyxeos, Defitelio, and Zepzelca. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Receive JAZZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jazz Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

JAZZ Stock News Headlines

November 30, 2022 | marketbeat.com

Struggling Axsome Stock Could Bounce Back on Drug Trial Success (JAZZ)

Axsome Pharmaceuticals may be struggling to get out of the red but the success of two very recent drug trials could quickly change all of that.

November 23, 2022 | marketbeat.com

Three CBD Stocks to Dominate a Budding Industry (JAZZ)

The CBD industry is growing at a high 20% CAGR and is expected to more than triple in size over the next 6 to 7 years, that's a budding opportunity.

November 28, 2022 | finance.yahoo.com

Jazz Pharmaceuticals to Present Data Demonstrating Advancements in Epilepsy Outcomes at the 2022 American Epilepsy Society Annual Meeting

November 23, 2022 | americanbankingnews.com

Jazz Pharmaceuticals (NASDAQ:JAZZ) Rating Increased to Strong-Buy at StockNews.com

November 23, 2022 | americanbankingnews.com

Brokerages Set Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Price Target at $202.50

November 21, 2022 | finance.yahoo.com

Jazz Pharma's (JAZZ) Gets FDA Nod for Rylaze's New Dosing Option

November 18, 2022 | finance.yahoo.com

Jazz Pharmaceuticals Announces U.S. FDA Approval of Monday/Wednesday/Friday Intramuscular Dosing Schedule for Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn)

November 14, 2022 | finance.yahoo.com

STAND UP TO CANCER LAUNCHES NEW RADIO PSA WITH JAZZ PHARMACEUTICALS TO ENCOURAGE LUNG CANCER SCREENING

November 11, 2022 | finance.yahoo.com

Implied Volatility Surging for Jazz Pharmaceuticals (JAZZ) Stock Options

November 11, 2022 | finance.yahoo.com

Jazz Pharmaceuticals Third Quarter 2022 Earnings: EPS Misses Expectations

November 10, 2022 | msn.com

Jazz Pharmaceuticals Announces Q3 2022 Financial Results, Raises Total Revenue Guidance

November 10, 2022 | markets.businessinsider.com

What 5 Analyst Ratings Have To Say About Jazz Pharmaceuticals

November 9, 2022 | finanznachrichten.de

Jazz Pharmaceuticals plc: Jazz Pharmaceuticals Announces Third Quarter 2022 Financial Results and Raises Total Revenue Guidance Mid-point

November 9, 2022 | finance.yahoo.com

Jazz Pharmaceuticals Announces Third Quarter 2022 Financial Results and Raises Total Revenue Guidance Mid-point

November 8, 2022 | finance.yahoo.com

Why Jazz Pharmaceuticals (JAZZ) Might Surprise This Earnings Season

November 3, 2022 | finanznachrichten.de

Jazz Pharmaceuticals plc: Jazz Pharmaceuticals to Present Data at 2022 ASH Meeting Showcasing Commitment to Advancing Oncology Research

November 3, 2022 | finance.yahoo.com

Jazz Pharmaceuticals to Present Data at 2022 ASH Meeting Showcasing Commitment to Advancing Oncology Research

October 31, 2022 | finance.yahoo.com

Zacks.com featured highlights include Albemarle, Chevron, Jazz Pharmaceuticals and Cummins

October 26, 2022 | finance.yahoo.com

Jazz Pharma's Zepzelca For Lung Cancer Flunked Confirmatory Trial, But FDA Will Not Pull Accelerated Approval

October 26, 2022 | marketwatch.com

Oligonucleotide Therapeutics Market Size with SWOT Analysis is Likely to Accelerate Industry Growth in Healthcare, Pharmaceuticals

October 24, 2022 | finance.yahoo.com

Wall Street Analysts Predict a 48% Upside in Jazz (JAZZ): Here's What You Should Know

October 20, 2022 | marketwatch.com

Jazz Pharmaceuticals, Zymeworks in Zanidatamab License Pact

October 19, 2022 | msn.com

Zymeworks and Jazz Pharmaceuticals ink $50M deal with potential for more

October 19, 2022 | finance.yahoo.com

Morrisville drugmaker sees promise in depression treatment, advances to pivotal study

October 19, 2022 | benzinga.com

Zymeworks To Host Conference Call on Exclusive Licensing Agreement of Zanidatamab

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive JAZZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jazz Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

JAZZ Company Calendar

Last Earnings: 11/09/2021
Today: 12/01/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 3/07/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Pharmaceuticals
Sector: Medical
Current Symbol: NASDAQ:JAZZ
CUSIP: G5087110
CIK: 1232524
Web: www.jazzpharma.com
Phone: (531) 634-7800
Fax: 353-1634-7850
Employees: 3,200
Year Founded: 2003

Price Target and Rating

Average Stock Price Forecast: $202.50
High Stock Price Forecast: $225.00
Low Stock Price Forecast: $187.00
Forecasted Upside/Downside: +29.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.80
Research Coverage: 10 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.30)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 10.60
P/E Growth: 0.93
Net Income: $-329,670,000.00
Net Margins: -0.52%
Pretax Margin: -2.17%
Return on Equity: 30.71%
Return on Assets: 9.10%

Debt

Debt-to-Equity Ratio: 2.07
Current Ratio: 3.16
Quick Ratio: 2.27

Sales & Book Value

Annual Sales: $3.09 billion
Price / Sales: 3.19
Cash Flow: $23.09 per share
Price / Cash Flow: 6.78
Book Value: $43.60 per share
Price / Book: 3.59

Miscellaneous

Outstanding Shares: 62,966,000
Free Float: 60,195,000
Market Cap: $9.86 billion
Optionable: Optionable
Beta: 0.74

Social Links

Key Executives

Bruce C. Cozadd
Chairman & Chief Executive Officer

Daniel N. Swisher
President

Christopher John Tovey
Chief Operating Officer & Executive Vice President

Renée D. Galá
Chief Financial Officer & Executive Vice President

Robert Iannone
Chief Medical Officer, EVP-Research & Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

JAZZ Stock - Frequently Asked Questions

Should I buy or sell Jazz Pharmaceuticals stock right now?: 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jazz Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" JAZZ shares.
View JAZZ analyst ratings or view top-rated stocks.
What is Jazz Pharmaceuticals' stock price forecast for 2023?: 10 equities research analysts have issued twelve-month price targets for Jazz Pharmaceuticals' stock. Their JAZZ share price forecasts range from $187.00 to $225.00. On average, they predict the company's stock price to reach $202.50 in the next twelve months. This suggests a possible upside of 29.4% from the stock's current price.
View analysts price targets for JAZZ or view top-rated stocks among Wall Street analysts.
How have JAZZ shares performed in 2022?: Jazz Pharmaceuticals' stock was trading at $127.40 at the beginning of the year. Since then, JAZZ stock has increased by 22.9% and is now trading at $156.54.
View the best growth stocks for 2022 here.
When is Jazz Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our JAZZ earnings forecast.
How were Jazz Pharmaceuticals' earnings last quarter?: Jazz Pharmaceuticals plc (NASDAQ:JAZZ) announced its quarterly earnings data on Tuesday, November, 9th. The specialty pharmaceutical company reported $4.20 earnings per share for the quarter, topping analysts' consensus estimates of $2.60 by $1.60. The specialty pharmaceutical company earned $838.12 million during the quarter, compared to analysts' expectations of $829.98 million. Jazz Pharmaceuticals had a negative net margin of 0.52% and a positive trailing twelve-month return on equity of 30.71%. During the same quarter last year, the business posted $3.86 earnings per share.
What guidance has Jazz Pharmaceuticals issued on next quarter's earnings?: Jazz Pharmaceuticals updated its FY22 earnings guidance on Wednesday, November, 9th. The company provided EPS guidance of $17.20-17.85 for the period, compared to the consensus earnings per share estimate of $17.30. The company issued revenue guidance of $3.6-3.7 billion, compared to the consensus revenue estimate of $3.64 billion.
What is Bruce C. Cozadd's approval rating as Jazz Pharmaceuticals' CEO?: 60 employees have rated Jazz Pharmaceuticals Chief Executive Officer Bruce C. Cozadd on Glassdoor.com. Bruce C. Cozadd has an approval rating of 92% among the company's employees. This puts Bruce C. Cozadd in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Jazz Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Jazz Pharmaceuticals investors own include Ligand Pharmaceuticals (LGND), Gilead Sciences (GILD), Alibaba Group (BABA), Micron Technology (MU), NVIDIA (NVDA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV), Bank of America (BAC) and Biogen (biib).
What is Jazz Pharmaceuticals' stock symbol?: Jazz Pharmaceuticals trades on the NASDAQ under the ticker symbol "JAZZ."
Who are Jazz Pharmaceuticals' major shareholders?: Jazz Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (10.39%), Vanguard Group Inc. (9.35%), State Street Corp (3.64%), LSV Asset Management (2.82%), Polaris Capital Management LLC (2.35%) and Renaissance Technologies LLC (2.06%). Insiders that own company stock include Anne Oriordan, Bruce C Cozadd, Bruce C Cozadd, Christopher J Tovey, Elmar Schnee, Finbar Larkin, James E Flynn, Kenneth W O'keefe, Kim Sablich, Mark Douglas Smith, Michael Patrick Miller, Neena M Patil, Patricia Carr, Patrick G Enright, Paul L Berns, Peter Gray, Samantha Pearce and Seamus Mulligan.
View institutional ownership trends.
How do I buy shares of Jazz Pharmaceuticals?: Shares of JAZZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Jazz Pharmaceuticals' stock price today?: One share of JAZZ stock can currently be purchased for approximately $156.54.
How much money does Jazz Pharmaceuticals make?: Jazz Pharmaceuticals (NASDAQ:JAZZ) has a market capitalization of $9.86 billion and generates $3.09 billion in revenue each year. The specialty pharmaceutical company earns $-329,670,000.00 in net income (profit) each year or ($0.30) on an earnings per share basis.
How many employees does Jazz Pharmaceuticals have?: The company employs 3,200 workers across the globe.
Does Jazz Pharmaceuticals have any subsidiaries?: The following companies are subsidiares of Jazz Pharmaceuticals: Cavion.
Read More
How can I contact Jazz Pharmaceuticals?: Jazz Pharmaceuticals' mailing address is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. The official website for the company is www.jazzpharma.com. The specialty pharmaceutical company can be reached via phone at (531) 634-7800, via email at investorinfo@jazzpharma.com, or via fax at 353-1634-7850.

This page (NASDAQ:JAZZ) was last updated on 12/2/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial